Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial

The heterogeneity both within and between breast cancers presents a significant clinical challenge for both diagnosis and therapy. this heterogeneity is present at all levels of analysis in breast cancer, ranging from genomic to metabolomic. a function of this heterogeneity is that numerous signaling networks are activated, and while treatment of one arm be initially effective, this allows the tumor to be poised to evolve a resistance mechanism. here we review the classification of breast cancers and discuss therapy of hormone positive, her2 positive, and triple negative breast cancers. model systems for breast cancer are examined allowing for a preclinical trial using a personalized medicine approach to be tested. this preclinical trial was based solely on cell signaling pathway activation and effectively and specifically blocked tumor growth in a preclinical model system.